Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Second Quarter 2022 Financial Results
08 août 2022 16h01 HE | FibroGen, Inc.
Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021Continued significant...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Second Quarter 2022 Financial Results
25 juil. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
08 juin 2022 07h00 HE | FibroGen, Inc.
- 73 Ambulatory DMD Patients Enrolled -- Topline Data Anticipated 2H:2023 - SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
Fibrogen_US_Primary_logo_RGB_M01.jpg
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
16 juin 2021 08h00 HE | FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2021 Financial Results
03 mai 2021 07h00 HE | FibroGen, Inc
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close. FibroGen will also...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Second Quarter 2020 Financial Results
23 juil. 2020 07h00 HE | FibroGen, Inc
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at Upcoming Investor Conferences
27 mai 2020 07h00 HE | FibroGen, Inc
SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...